{
    "clinical_study": {
        "@rank": "55370", 
        "arm_group": [
            {
                "arm_group_label": "Pulmonary Hypertension & WHO group I", 
                "description": "Participants with Pulmonary Hypertension with a WHO classification group I and are scheduled to have a right heart catheterization."
            }, 
            {
                "arm_group_label": "Pulmonary Hypertension & WHO group II", 
                "description": "Participants with Pulmonary Hypertension with a WHO classification group II and are scheduled to have a right heart catheterization."
            }, 
            {
                "arm_group_label": "Without Pulmonary Hypertension", 
                "description": "Participants without Pulmonary Hypertension"
            }, 
            {
                "arm_group_label": "Connective Tissue Disease", 
                "description": "Participants without PH, but with connective tissue disease"
            }
        ], 
        "biospec_descr": {
            "textblock": "whole blood"
        }, 
        "biospec_retention": "Samples With DNA", 
        "brief_summary": {
            "textblock": "The investigators are testing whether the addition of Pulmonary Hypertension-related\n      biomarkers, measured across the pulmonary circulation, to the standard hemodynamic\n      evaluation for Pulmonary Hypertension will lead to more informed choices of Pulmonary\n      Hypertension therapy and improved patient outcomes."
        }, 
        "brief_title": "Trans-pulmonary Biomarkers in Pulmonary Hypertension", 
        "completion_date": {
            "#text": "August 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Pulmonary Hypertension", 
        "condition_browse": {
            "mesh_term": [
                "Hypertension", 
                "Hypertension, Pulmonary"
            ]
        }, 
        "detailed_description": {
            "textblock": "Eligible participants with known or suspected Pulmonary Hypertension undergoing a clinically\n      indicated right heart catheterization may be enrolled. Clinical data and blood samples will\n      be analyzed."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Age \u2265 18 years old\n\n          -  Undergoing RHC for PH evaluation\n\n        Exclusion Criteria:\n\n          -  Anemia defined as Hgb < 10 g/dL and HCT < 30\n\n          -  Pregnancy at the time of RHC (as assessed by urine or serum pregnancy test on the day\n             of the procedure)\n\n          -  Left ventricular ejection fraction \u2264 40%\n\n          -  Atrial fibrillation at the time of RHC (as defined by telemetry monitoring or EKG on\n             the day of the procedure)\n\n          -  IPF, CTEPH, COPD/OSA as the dominant etiology of PH\n\n          -  Patient is currently taking PH medication or long-acting nitrates at the time of\n             their RHC."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years", 
            "sampling_method": "Probability Sample", 
            "study_pop": {
                "textblock": "Pulmonary Vascular Clinic"
            }
        }, 
        "enrollment": {
            "#text": "100", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 19, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01961232", 
            "org_study_id": "IRB090650"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Pulmonary Hypertension", 
            "biomarker", 
            "cardiac", 
            "circulation", 
            "heart disease", 
            "lung disease"
        ], 
        "lastchanged_date": "October 10, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Nashville", 
                    "country": "United States", 
                    "state": "Tennessee", 
                    "zip": "37232"
                }, 
                "name": "Vanderbilt University Medical Center"
            }, 
            "investigator": {
                "last_name": "Kenneth Monahan, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_groups": "4", 
        "official_title": "Examination of Trans-pulmonary Biomarkers in Pulmonary Hypertension: a Potential Step Towards Personalized Therapy", 
        "other_outcome": {
            "measure": "Differences between Pulmonary Hypertension-related biomarkers in pulmonary circulation and  peripheral-venous circulation", 
            "safety_issue": "No", 
            "time_frame": "At baseline"
        }, 
        "overall_contact": {
            "email": "laura.e.maynard@vanderbilt.edu", 
            "last_name": "Laura Maynard, RN", 
            "phone": "615-936-1720"
        }, 
        "overall_official": {
            "affiliation": "Vanderbilt University", 
            "last_name": "Ken Monahan, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "August 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Differences in Pulmonary Hypertension biomarkers in patients evaluated for Pulmonary Hypertension", 
            "safety_issue": "No", 
            "time_frame": "At baseline"
        }, 
        "reference": {
            "PMID": "24015334", 
            "citation": "Monahan K, Scott TA, Su YR, Lenneman CG, Zhao DX, Robbins IM, Hemnes AR. Reproducibility of intracardiac and transpulmonary biomarkers in the evaluation of pulmonary hypertension. Pulm Circ. 2013 Apr;3(2):345-9. doi: 10.4103/2045-8932.114762."
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01961232"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Vanderbilt University", 
            "investigator_full_name": "Kenneth Monahan", 
            "investigator_title": "Assistant Professor", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "measure": "Vasodilator-induced changes in Pulmonary Vascular Resistance (PVR)", 
                "safety_issue": "No", 
                "time_frame": "At baseline"
            }, 
            {
                "measure": "Vasodilator-induced changes in Pulmonary Hypertension biomarkers", 
                "safety_issue": "No", 
                "time_frame": "At baseline"
            }
        ], 
        "source": "Vanderbilt University", 
        "sponsors": {
            "collaborator": {
                "agency": "Gilead Sciences", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Vanderbilt University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "August 2013", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "October 2013"
    }
}